MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company's product candidate includes MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders consisting of primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction. Its product pipeline also comprises MN-221 (bedoradrine), a selective -adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, and other fibrotic diseases; and MN-029 (denibulin), a tubulin binding agent to treat solid tumor cancers. The company was founded in 2000 and is headquartered in La Jolla, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MNOV
CUSIPN/A
Phone858-373-1500
Debt
Debt-to-Equity RatioN/A
Current Ratio41.41
Quick Ratio41.41
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.07 per share
Price / Book8.66
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-11,160,000.00
Net MarginsN/A
Return on Equity-23.28%
Return on Assets-21.67%
Miscellaneous
Employees9
Outstanding Shares41,880,000
Market Cap$395.34 million
MediciNova (NASDAQ:MNOV) Frequently Asked Questions
What is MediciNova's stock symbol?
MediciNova trades on the NASDAQ under the ticker symbol "MNOV."
How were MediciNova's earnings last quarter?
MediciNova, Inc. (NASDAQ:MNOV) released its quarterly earnings results on Thursday, October, 29th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.10) by $0.04. View MediciNova's Earnings History.
When is MediciNova's next earnings date?
What price target have analysts set for MNOV?
1 brokers have issued 1 year price objectives for MediciNova's stock. Their predictions range from $22.00 to $22.00. On average, they expect MediciNova's stock price to reach $22.00 in the next year. This suggests a possible upside of 137.3% from the stock's current price. View Analyst Price Targets for MediciNova.
What is the consensus analysts' recommendation for MediciNova?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediciNova in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MediciNova.
Who are some of MediciNova's key competitors?
Some companies that are related to MediciNova include Allakos (ALLK), Theravance Biopharma (TBPH), Corcept Therapeutics (CORT), ARMO Biosciences (ARMO), Amneal Pharmaceuticals (AMRX), Arrowhead Pharmaceuticals (ARWR), TESARO (TSRO), Myovant Sciences (MYOV), IMMURON Ltd/S (IMRN), Innoviva (INVA), Impax Laboratories (IPXL), Deciphera Pharmaceuticals (DCPH), ImmunoGen (IMGN), Alder Biopharmaceuticals (ALDR) and Uniqure (QURE).
Who are MediciNova's key executives?
MediciNova's management team includes the folowing people:
- Dr. Yuichi Iwaki, Co-Founder, Pres, CEO & Exec. Director (Age 68)
- Mr. Ryan J. Selhorn, CFO & Principal Accounting Officer (Age 36)
- Mr. Masatsune Okajima, Head of Japanese Office and VP (Age 50)
- Dr. Kazuko Matsuda M.D., Ph.D., MPH, Chief Medical Officer (Age 52)
- Mr. Geoffrey G. O'Brien J.D., M.B.A., VP (Age 49)
Has MediciNova been receiving favorable news coverage?
News coverage about MNOV stock has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. MediciNova earned a news impact score of 0.11 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 48.14 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term. View Recent Headlines for MediciNova.
Who are MediciNova's major shareholders?
MediciNova's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.67%), SATOMI HAJIME (5.30%), FMR LLC (1.62%), Bank of New York Mellon Corp (0.36%), Schwab Charles Investment Management Inc. (0.19%) and American Century Companies Inc. (0.17%). Company insiders that own MediciNova stock include Yoshio Ishizaka and Yutaka Kobayashi. View Institutional Ownership Trends for MediciNova.
Which institutional investors are selling MediciNova stock?
Which institutional investors are buying MediciNova stock?
MNOV stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., American Century Companies Inc., Bank of New York Mellon Corp, California Public Employees Retirement System, Commonwealth Equity Services LLC, Schwab Charles Investment Management Inc. and Alps Advisors Inc.. Company insiders that have bought MediciNova stock in the last two years include Yoshio Ishizaka and Yutaka Kobayashi. View Insider Buying and Selling for MediciNova.
How do I buy shares of MediciNova?
Shares of MNOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MediciNova's stock price today?
One share of MNOV stock can currently be purchased for approximately $9.27.
How big of a company is MediciNova?
MediciNova has a market capitalization of $395.34 million. MediciNova employs 9 workers across the globe.
How can I contact MediciNova?
MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-373-1500 or via email at [email protected]
MarketBeat Community Rating for MediciNova (NASDAQ MNOV)
MarketBeat's community ratings are surveys of what our community members think about MediciNova and other stocks. Vote "Outperform" if you believe MNOV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNOV will underperform the S&P 500 over the long term. You may vote once every thirty days.
